Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037109 · ClinicalTrials.gov registry record
VIDAS® NEPHROCLEAR Reference Interval Study
A clinical trial, sponsored by BioMérieux.
- Completed
- Registry status
- 585
- Enrollment target
NCT06037109: Completed study, sponsored by BioMérieux.
NCT06037109 is a clinical trial that has completed, run by BioMérieux. The registered enrollment target is 585 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06037109 has completed, sponsored by BioMérieux.
- COMPLETED
- Registry status
- 585 participants
- Enrollment target
Study Summary
This is a multi-center sample analysis study in which urine samples previously collected from apparently healthy adult subjects, and subjects with stable chronic morbidities but without AKI in order to establish the reference range for the VIDAS® NEPHROCLEAR™ CCL14 test.
Primary Outcome
CCL14 concentration will be measured using the VIDAS Necphroclear CCL14 Assay
Interventions
- DEVICE Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 585 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2023-12-28 |
What the finished NCT06037109 record still lists
NCT06037109 is an observational study that tracks outcomes without assigning an intervention. The registered 585 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test is the first listed.
NCT06037109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06037109 about?
NCT06037109 is a clinical study titled "VIDAS® NEPHROCLEAR Reference Interval Study". This is a multi-center sample analysis study in which urine samples previously collected from apparently healthy adult subjects, and subjects with stable chronic morbidities but without AKI in order to establish the reference range for the VIDAS® NEPHROCLEAR™ CCL14 test.
What is the current status of trial NCT06037109?
This trial is currently completed. The enrollment target is 585 participants. The study started on 2023-07-18. Estimated completion is 2023-12-28.
What interventions are being tested in trial NCT06037109?
The interventions under investigation include: Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test (DEVICE).
Who is sponsoring clinical trial NCT06037109?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02803957 · 585 participants · NA
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
- NCT06680869 · 585 participants · Phase 3
Early Amiodarone in Shockable Cardiac Arrest
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI